Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today, ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) ...
Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. In this phase 3, double-blind, randomized, ...
Here’s what to know about the 12-3-30 workout. By Danielle Friedman See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add The New York ...
The biggest stories of the day delivered to your inbox.
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...
Contract strengthens the company’s growing portfolio of U.S. government-funded PNT initiatives TrustPoint announces it has been awarded by AFWERX a SBIR Direct-to-Phase II contract in the amount of $1 ...
VESPER-3 reinforces confidence in monthly dosing of PF-08653944 (MET-097i), including the potential for higher dosing regimens in Phase 3 Study met primary endpoint of statistically significant weight ...
Boys’ reading struggles are not inevitable, research suggests, and addressing the deficit could improve outcomes in school and beyond. By Claire Cain Miller Claire Cain Miller is working on a series ...
Trials aim to optimize frontline therapies for CLL, multiple myeloma, SLL, and pediatric acute leukemia/MDS, focusing on high-risk, treatment-naïve patients. Investigations include BTK inhibitors, CAR ...
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results